Cite
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
MLA
Anil K. Sood, et al. “Phase II Trial of Bevacizumab with Dose-Dense Paclitaxel as First-Line Treatment in Patients with Advanced Ovarian Cancer.” Gynecologic Oncology, vol. 147, no. 1, Apr. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b04028d8859e42b4101c377ed06dad54&authtype=sso&custid=ns315887.
APA
Anil K. Sood, Nicole D. Fleming, Robert L. Coleman, Mark F. Munsell, Shannon N. Westin, Yunjie Sun, Wei Hu, Priya Bhosale, & Celestine S. Tung. (2017). Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecologic Oncology, 147(1).
Chicago
Anil K. Sood, Nicole D. Fleming, Robert L. Coleman, Mark F. Munsell, Shannon N. Westin, Yunjie Sun, Wei Hu, Priya Bhosale, and Celestine S. Tung. 2017. “Phase II Trial of Bevacizumab with Dose-Dense Paclitaxel as First-Line Treatment in Patients with Advanced Ovarian Cancer.” Gynecologic Oncology 147 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b04028d8859e42b4101c377ed06dad54&authtype=sso&custid=ns315887.